Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laser immunotherapy with and without topical anti-PD1 in basal cell carcinomas
2019-003310-14Phase 2Completed
- Sponsor
- Department of Dermatology, Bispebjerg Hospital
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in basal cell carcinoma (BCC) (3 arms), sponsored by Department of Dermatology, Bispebjerg Hospital. Primary endpoint: Immunological response by IHC. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2019-003310-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003310-14.